Autolus Secures $250M Credit Line as AUCATZYL Revenue Surges
Event summary
- Autolus reports preliminary Q2 2026 AUCATZYL revenue of $45M, up ~70% QoQ and ~100% YoY.
- Company secures $250M credit facility with Perceptive Advisors, $75M drawn at closing.
- FY 2026 sales guidance raised to $140–$150M from $120–$135M.
- Gross margin improves to ~35% YoY from negative ~20% in H2 2025.
The big picture
Autolus's strong revenue growth and improved profitability signal a turning point for its commercial-stage therapy AUCATZYL. The $250M credit facility from Perceptive Advisors provides flexibility to expand into larger autoimmune markets, where obe-cel could become a key growth driver. This financing comes as the biopharma sector increasingly prioritizes capital efficiency amid volatile funding conditions.
What we're watching
- Commercial Momentum
- Whether Autolus can sustain AUCATZYL's rapid adoption in new treatment centers.
- Capital Deployment
- How the company allocates the $250M credit facility across oncology and autoimmune programs.
- Margin Expansion
- The pace at which gross margins improve as operational efficiencies scale.
Related topics